A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

Hepatitis B, Chronic Clinical Trial

Official title:

A Single Center, Open Labeled Phase I/IIa Study to Evaluate Safety, Tolerability and Efficacy of a Therapeutic Hepatitis B Vaccine in Oral Antiviral Drug-treated Chronic Hepatitis B Virus Carriers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02693652
• Other study ID #: CVI-HBV-002-CT1301
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 28, 2014
• Est. completion date: August 22, 2017

Study information

• Verified date: November 2023
• Source: CHA Vaccine Institute Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers

Description:

- Objectives: To explore the appropriate dose of a therapeutic hepatitis B vaccine through the evaluation of safety, tolerability, and efficacy - Subjects: Chronic hepatitis B carrier with normal ALT range - Study hypothesis: The immune tolerance break and strong immune responses in the chronic hepatitis B carrier could be achieved with therapeutic hepatitis B vaccine containing novel adjuvant

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: August 22, 2017
• Est. primary completion date: August 22, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Adult between 19 to 60 years of age

2. Chronic hepatitis B carriers (HBsAg positive over 6 months)

3. HBeAg positive patient, or patient who had lost HBeAg during Antiviral drug treatment

4. Antiviral drug treated patient reducing the HBV DNA level below 2000 IU/mL measured by COBAS TaqManM HBV Test (Duration of drug administration should be over 6 months and no limitation on the type of antiviral drug)

5. Patient has low ALT than 1.1 fold of upper limit of normal ALT level at screening

6. Patient is able to provide written informed consent by oneself or legal representative

Exclusion Criteria:

1. Patient has liver diseases except chronic hepatitis B (i.e. hematochromatosis, alcoholic liver disease, nonalcoholic fatty liver disease, alpha-1 antitrypsin deficiency etc.)

2. Patient has one or more test results and symptoms at the screening

• ALT > upper limit of normal level X 1.1
• Total bilirubin > upper limit of normal
• Prothrombin time > Over 3 second than normal
• Serum Albumin < 30 g/L (3 g/dL)
• Patient has history of ascites, yellow jaundice, variceal hemorrhage, hepatic encephalopathy, or liver failure
• Liver FibroScan > F3 (F0: no fibrosis, F1: portal fibrosis, F2: periportal fibrosis, F3: septal fibrosis, F4: cirrhosis)

3. Patient has one or more test results at the screening

• Hemoglobin < 9.0 g/dL
• Absolute neutrophil count (ANC) < 1.5 x 109 /L (1500 /mm3)
• Platelet count < 100 x 109 /L (100 x 103 /mm3)
• Serum creatinine > 1.5 mg/dL
• Serum amylase > 2 x ULN and Lipase > 2 x ULN

4. Patient has history of Interferon treatment

5. Patient is pregnant or breastfeeding or intending to become pregnant during the study

6. Patient has active microbial, viral, or fungal infections in need of systemic treatment

7. Alpha-fetoprotein (AFP) > 50 ng/mL or Hepatocellular Carcinoma (HCC) patient

8. Among the patients treated with immunosuppressive drug within 6 months before screening, suspected case of the declined immunity in the opinion of the investigator

9. Patient had long term systemic treatment (more than 14 days consecutively) of high dose (over 20 mg of prednisolone or equivalent dose*) corticosteroid (Decision to participate of patient who had local treatment of corticosteroid is allowed in the opinion of the investigator) *equivalent to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg, methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, or betamethasone 2.4 mg

10. Patient diagnosed with a malignant tumor within 5 years before screening or relapsed patient (Benign tumor patient is able to participate in this study at the discretion of the investigator)

11. Patient has history of organ transplantation

12. Patient has serious disease judged by investigator such as heart failure, renal failure, and pancreatitis

13. Patient has history of serious heart disease (NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, treatment required ventricular tachyarrhythmias, or unstable angina etc.)

14. Patient has seizure disorder required anticonvulsants treatment

15. Uncontrollable diabetic patient (FBS>130mg/dl, HbA1c>7.5%)

16. Uncontrollable hypertension patient (SBP=140mmHg ?? DBP=90mmHg)

17. HCV, HDV, or HIV patient

18. Patient has a plan to participate in other clinical study, or took part in other clinical study within 1 month before enrollment

19. Patient has hypersensitivity or anaphylactic reaction for components of investigational product or HBV vaccine

20. Patient has continuous drinking (>21 units/week, 1 unit = 10g of pure alcohol) or dependence on alcohol

21. Patient concerned about the decline in daily activity or not able to understand the objectives and methods due to the psychiatric problems

22. Patient has potential to severe febrile or systemic reaction

23. Subject unacceptable in this study under the opinion of the investigator

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic

Intervention

Biological:
• CVI-HBV-002
Investigational product: CVI-HBV-002 Dose: 20ug or 40ug Frequency: 3 or 6 times Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months Administration route: Intramuscular injection

Locations

Country	Name	City	State
Korea, Republic of	Bundang CHA General Hospital	Seongnam-si	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
CHA Vaccine Institute Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability (including incidence of adverse events or expected adverse reactions for vaccine treatment) measured for 7 days after each vaccination	Occurrence of severe local and/or systemic tolerability signs and symptoms measured for 7 days after each vaccination	7 days after each vaccination
Secondary	HBeAg loss	HBeAg disappearance at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline	at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary	HBe seroconversion rate	HBeAg seroconversion rate at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline	at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary	HBsAg loss	HBsAg disappearance at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline	at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary	HBsAg seroconversion rate	HBsAg seroconversion rate at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline	at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)
Secondary	HBV specific T cell immunity	HBV specific T cell response at the 3rd month (for 3 shot group) or 6th month (for 6 shot group) comparing with that of baseline	at the 3rd month (for 3 shot group) or 6th month (for 6 shot group)
Secondary	HBV DNA level	HBV DNA level at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group) comparing with that of baseline	at the 3rd and 5th month (for 3 shot group) or 6th and 8th month (for 6 shot group)